top of page

EPIZYME Educational Program ~ 4/28/21

Registration Information

Date: Wednesday, April 28, 2021 Start Time: 12:00 PM ET Speaker(s): John Pagel, MD, PhD Hosted by: Amanda Erickson Program Topic: Epizyme Educational Program Virtual Webcast

TAZVERIK® (tazemetostat) is indicated for the treatment of:

• Adult patients with relapsed or refractory (R/R) follicular

lymphoma (FL) whose tumors are positive for an EZH2

mutation as detected by an FDA-approved test and who

have received at least 2 prior systemic therapies

• Adult patients with R/R FL who have no satisfactory

alternative treatment options

These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

4.28.21 at 12pm Taz J.Pagel MD PhD
Download PDF • 332KB

31 views0 comments


bottom of page